Találati lista | Tudóstér

001-es BibID:	BIBFORM102567
035-os BibID:	(cikkazonosító)905585 (WoS)000827929000001 (Scopus)85133014637
Első szerző:	Kiss Zoltán
Cím:	Nationwide Effectiveness of First and Second SARS-CoV2 Booster Vaccines During the Delta and Omicron Pandemic Waves in Hungary (HUN-VE 2 Study) / Zoltan Kiss, István Wittmann, Lórinc Polivka, György Surján, Orsolya Surján, Zsófia Barcza, Gergő Attila Molnár, Dávid Nagy, Veronika Müller, Krisztina Bogos, Péter Nagy, István Kenessey, András Wéber, Mihály Pálosi, János Szlávik, Zsuzsa Schaff, Zoltán Szekanecz, Cecília Müller, Miklós Kásler, Zoltán Vokó
Dátum:	2022
ISSN:	1664-3224
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk SARS-CoV2 infection boobster vaccine 4th vaccine omicron variant (SARS-Co-V2) delta variant (B.1.617.2) vaccine effectiveness mortalitiy
Megjelenés:	Frontiers in Immunology. - 13 (2022), p. 1-9. -
További szerzők:	Wittmann István Polivka Lőrinc Surján György Surján Orsolya Barcza Zsófia Molnár Gergő Attila Nagy Dávid Müller Veronika Bogos Krisztina Nagy Péter (1976-) (vegyész) Kenessey István Wéber András Pálosi Mihály Szlávik János Schaff Zsuzsa Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Müller Cecília Kásler Miklós Vokó Zoltán (1968-) (epidemiológus)
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM097681
035-os BibID:	(cikkazonosító)725465 (WOS)000717701800001 (Scopus)85118968206
Első szerző:	Rokszin György
Cím:	Sodium-Glucose Co-Transporter 2 Inhibitors May Change the Development of Urinary Tract and Hematological Malignancies as Compared With Dipeptidyl Peptidase-4 Inhibitors : data of the Post-Hoc Analysis of a Nationwide Study / Rokszin György, Kiss Zoltán, Sütő Gábor, Kempler Péter, Jermendy György, Fábián Ibolya, Szekanecz Zoltán, Poór Gyula, Wittmann István, Molnár Gergő Attila
Dátum:	2021
ISSN:	2234-943X
Megjegyzések:	Background: In diabetes mellitus, during the last years, cancer became of equivalent importance as a cardiovascular disease in terms of mortality. In an earlier study, we have analyzed data of the National Health Insurance Fund (NHIF) of Hungary with regards all patients treated with sodium-glucose co-transporter 2 (SGLT2) inhibitors (SGLT2is) vs. those treated with dipeptidyl peptidase-4 (DPP-4) inhibitors (DPP-4is) in a given timeframe. In propensity score-matched groups of SGLT2i- vs. DPP-4i-treated patients, we found a lower incidence of cancer in general. In this post-hoc analysis, we aimed to obtain data on the incidence of site-specific cancer. Patients and Methods: All patients starting an SGLT2i or a DPP-4i between 2014 and 2017 in Hungary were included; the two groups (SGLT2i vs. DPP-4i) were matched for 54 clinical and demographical parameters. The follow-up period was 639 vs. 696 days, respectively. Patients with a letter "C" International Classification of Diseases, 10th Revision (ICD-10) code have been chosen, and those with a known malignancy within a year before the onset of the study have been excluded from the analysis. Results: We found a lower risk of urinary tract [HR 0.50 (95% CI: 0.32?0.79) p = 0.0027] and hematological malignancies [HR 0.50 (95% CI: 0.28?0.88) p = 0.0174] in patients treated with SGLT2i vs. those on DPP-4i. Risk of other types of cancer (including lung and Frontiers in Oncology \| www.frontiersin.org 1 October 2021 \| Volume 11 \| Article 725465 Edited by: Vincenzo Quagliariello, Istituto Nazionale Tumori Fondazione G. Pascale (IRCCS), Italy Reviewed by: Keizo Kanasaki, Shimane University, Japan Yoshifumi Saisho, Keio University, Japan *Correspondence: Istva? n Wittmann wittmann.istvan@pte.hu Specialty section: This article was submitted to Molecular and Cellular Oncology, a section of the journal Frontiers in Oncology Received: 29 June 2021 Accepted: 30 September 2021 Published: 28 October 2021 Citation: Rokszin G, Kiss Z, Süto? G, Kempler P, Jermendy G, Fa? bia? n I, Szekanecz Z, Poo? r G, Wittmann I and Molna?r GA (2021) Sodium-Glucose CoTransporter 2 Inhibitors May Change the Development of Urinary Tract and Hematological Malignancies as Compared With Dipeptidyl Peptidase4 Inhibitors: Data of the Post-Hoc Analysis of a Nationwide Study. Front. Oncol. 11:725465. doi: 10.3389/fonc.2021.725465 ORIGINAL RESEARCH published: 28 October 2021 doi: 10.3389/fonc.2021.725465 larynx, lower gastrointestinal (GI) tract, rectum, pancreas, non-melanoma skin cancers, breast, or prostate) did not differ significantly between the two groups. When plotting absolute risk difference against follow-up time, an early divergence of curves was found in case of prostate, urinary tract, and hematological malignancies, whereas late divergence can be seen in case of cancers of the lung and larynx, the lower GI tract, and the breast. Conclusions: Urinary tract and hematological malignancies were less frequent in patients treated with SGLT2i vs. DPP-4i. An early vs. late divergence could be observed for different cancer types, which deserves further studies.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk diabetes mellitus type 2 cancer antidiabetic treatment dipeptidyl peptidase (DPP)-4 inhibitors sodiumglucose co-transporter 2 (SGLT 2) inhibitors
Megjelenés:	Frontiers in Oncology. - 11 (2021), p. 1-9. -
További szerzők:	Kiss Zoltán (Budapest) Sütő Gábor Kempler Péter (1954-) (belgyógyász, diabetológus) Jermendy György Fábián Ibolya Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Poór Gyula Wittmann István Molnár Gergő Attila
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM091281
035-os BibID:	(cikkazonosító)e001765
Első szerző:	Sütő Gábor
Cím:	Risk of morbidity and mortality in patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor and/or dipeptidyl peptidase-4 inhibitor : a nationwide study / Gábor Sütő, Gergő A. Molnár, György Rokszin, Ibolya Fábián, Zoltán Kiss, Zoltán Szekanecz, Gyula Poór, György Jermendy, Péter Kempler, István Wittmann
Dátum:	2021
ISSN:	2052-4897
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	BMJ Open Diabetes Research & Care. - 9 : 1 (2021), p. 1-10. -
További szerzők:	Molnár Gergő Attila Rokszin György Fábián Ibolya Kiss Zoltán Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Poór Gyula Jermendy György Kempler Péter (1954-) (belgyógyász, diabetológus) Wittmann István
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM103047
035-os BibID:	(cikkazonosító)919408 (WoS)000836947300001 (Scopus)85135452371
Első szerző:	Vokó Zoltán (epidemiológus)
Cím:	Effectiveness and Waning of Protection With Different SARS-CoV-2 Primary and Booster Vaccines During the Delta Pandemic Wave in 2021 in Hungary (HUN-VE 3 Study) / Zoltán Vokó, Zoltán Kiss, György Surján, Orsolya Surján, Zsófia Barcza, István Wittmann, Gergő Attila Molnár, Dávid Nagy, Veronika Müller, Krisztina Bogos, Péter Nagy, István Kenessey, András Wéber, Lőrinc Polivka, Mihály Pálosi, János Szlávik, György Rokszin, Cecília Müller, Zoltán Szekanecz, Miklós Kásler
Dátum:	2022
ISSN:	1664-3224
Megjegyzések:	Background: In late 2021, the pandemic wave was dominated by the Delta SARS-CoV-2 variant in Hungary. Booster vaccines were offered for the vulnerable population starting from August 2021. Methods: The nationwide HUN-VE 3 study examined the effectiveness and durability of primary immunization and single booster vaccinations in the prevention of SARS-CoV-2 infection, Covid-19 related hospitalization and mortality during the Delta wave, compared to an unvaccinated control population without prior SARS-CoV-2 infection. Results: The study population included 8,087,988 individuals who were 18?100 years old at the beginning of the pandemic. During the Delta wave, after adjusting for age, sex, calendar day, and chronic diseases, vaccine effectiveness (VE) of primary vaccination against registered SARS-CoV-2 infection was between 11% to 77% and 18% to 79% 14?120 days after primary immunization in the 16?64 and 65?100 years age cohort respectively, while it decreased to close to zero in the younger age group and around 40% or somewhat less in the elderly after 6 months for almost all vaccine types. In the population aged 65?100 years, we found high, 88.1%?92.5% adjusted effectiveness against Covid-19 infection after the Pfizer-BioNTech, and 92.2%?95.6% after the Moderna booster dose, while Sinopharm and Janssen booster doses provided 26.5%?75.3% and 72.9%?100.0% adjusted VE, respectively. Adjusted VE against Covid-19 related hospitalization was high within 14?120 days for Pfizer-BioNTech: 76.6%, Moderna: 83.8%, Sputnik-V: 78.3%, AstraZeneca: 73.8%, while modest for Sinopharm: 45.7% and Janssen: 26.4%. The waning of protection against Covid-19 related hospitalization was modest and booster vaccination with mRNA vaccines or the Janssen vaccine increased adjusted VE up to almost 100%, while the Sinopharm booster dose proved to be less effective. VE against Covid-19 related death after primary immunization was high or moderate: for Pfizer-BioNTech: 81.5%, Moderna: 93.2%, Sputnik-V: 100.0%, AstraZeneca: 84.8%, Sinopharm: 58.6%, Janssen: 53.3%). VE against this outcome also showed a moderate decline over time, while booster vaccine types restored effectiveness up to almost 100%, except for the Sinopharm booster. Conclusions: The HUN-VE 3 study demonstrated waning VE with all vaccine types for all examined outcomes during the Delta wave and confirmed the outstanding benefit of booster vaccination with the mRNA or Janssen vaccines, and this is the first study to provide clear and comparable effectiveness results for six different vaccine types after primary immunization against severe during the Delta pandemic wave.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk booster vaccine delta variant vaccine effectiveness sinopharm sputnik-V janssen Covid-19
Megjelenés:	Frontiers in Immunology. - 13 (2022), p. 1-9. -
További szerzők:	Kiss Zoltán Surján György Surján Orsolya Barcza Zsófia Wittmann István Molnár Gergő Attila Nagy Dávid Müller Veronika Bogos Krisztina Nagy Péter (1976-) (vegyész) Kenessey István Wéber András Polivka Lőrinc Pálosi Mihály Szlávik János Rokszin György Müller Cecília Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Kásler Miklós
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: